CardioDX Files for IPO
CardioDx has filed for an IPO. The number of shares to be offered and pricing terms have yet to be decided. CardioDX plans on listing its stock on the NASDAQ under the ticker symbol “CDX.” BofA Merrill Lynch and Jefferies LLC will serve as lead underwriters. Headquartered in Palo Alto, Calif., CardioDx is a molecular diagnostics company specializing in cardiovascular genomics. It is backed by Kleiner, Perkins, Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, GE Capital, Longitude Capital, JP Morgan, Acadia Woods Partners, Artiman Ventures, Bright Capital, and Temasek.